<!doctype html>
<html lang="en">
<head>
	<meta charset="UTF-8">
	<title>International Fabry Disease Genotype-Phenotype Database (dbFGP)</title>
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<link rel="stylesheet" href="../public/css/style.css">
	<link rel="stylesheet" type="text/css" href="./css/styles_search.css" />
</head>
<style>

</style>
<body>
<div class="container">
<?php include"header.php"; ?>
	<div class="content">
		<h2 style="font-family: 'Helvetica Neue', sans-serif; font-size: 18px; color:#3D1C00;font-weight: 700; line-height: 50px; letter-spacing: 1px;">
			The International Center for Fabry Disease (ICFD)
		</h2>

		<P style="border:0px solid red;text-align: left; color: #292929; display: inline-block; font-family: 'Georgia', serif; font-style: italic; font-size: 16px; line-height: 22px; margin: 0 0 20px 18px; padding: 1px 12px 8px; border-bottom: double #69D2E7;">
			Icahn School of Medicine at Mount Sinai<br>
			Department of Genetics and Genomic Sciences<br>
			New York, New York<br>
			Phone:  866-322-7963; Email:  fabry.disease@mssm.edu
		</p>
<br>
		<p style="text-align: left; width:50%; background-color:#fff;color: #292929; display: inline-block; font-family: 'Georgia', serif; font-size: 16px; font-weight: 500; line-height: 22px; margin: 0 90px 4px 90px; padding: 1px 10px 1px 10px;  border: 1px solid #fff">
			The International Center for Fabry Disease (ICFD) has provided diagnostic and clinical services to identify and
			evaluate affected males and heterozygous females with Fabry disease for over 40 years. The diagnostic studies
			include &alpha;-galactosidase A (&alpha;-Gal A) enzyme determinations in plasma and white blood cells, and mutation
			analysis of the &alpha;-galactosidase A (GLA) gene. In addition, the Center offers clinical evaluations, medical
			management, genetic counseling, and treatment for patients. The Center has performed diagnostic and clinical
			evaluations for over 3,000 patients during the last 40 years, and continues to perform research to improve
			diagnostic methods and treatment. The Center’s researchers were first to purify normal &alpha;-Gal A, isolate the &alpha;-Gal A
			cDNA and GLA gene, and identify the GLA mutations causing Fabry disease, generated the mouse model of
			Fabry disease, and performed the preclinical studies and subsequent clinical trials that led to the approval of Fabrazyme™, enzyme replacement therapy (ERT), for patients with Fabry disease.
		<br>
		<label style="text-align: left; background-color:#FFC219;color: #fff; display: inline-block; font-family: 'Georgia', serif; font-size: 16px; line-height: 22px; margin: 0 90px 4px 90px; padding: 10px 20px 10px 10px; float:right;width:200px;  border: 1px solid #fff">
			Click <a href="http://icahn.mssm.edu/research/programs/international-center-for-fabry-disease/references" style="text-decoration:none;color:white" target="_blank"><b>HERE</b> </a> for lists of the ICFD’s past and current publications
		</label>
		</p>


	</div>
	<?php include"footer.php"; ?>
</div>
</body>
</html>
